Australia's most trusted
source of pharma news
Monday, 06 May 2024
Posted 23 April 2024 AM
Gilead Sciences has forked out $400,000 across nine local organisations addressing viral hepatitis, aiding Australia in reaching the World Health Organisation's goal of eliminating viral hepatitis as a public health threat by 2030.
The funding announcement, which falls under the company's ALL4LIVER Grant coincided with World Liver Day last Friday.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.